View : 29 Download: 0

Association of Long-term Use of Low-Dose Aspirin as Chemoprevention With Risk of Lung Cancer

Title
Association of Long-term Use of Low-Dose Aspirin as Chemoprevention With Risk of Lung Cancer
Authors
Ye, ShinheeLee, MyeongjeeLee, DongheonHa, Eun-HeeChun, Eun Mi
Ewha Authors
하은희천은미이명지
SCOPUS Author ID
하은희scopus; 천은미scopus
Issue Date
2019
Journal Title
JAMA NETWORK OPEN
ISSN
2574-3805JCR Link
Citation
JAMA NETWORK OPEN vol. 2, no. 3
Publisher
AMER MEDICAL ASSOC
Indexed
SCOPUS WOS
Document Type
Article
Abstract
IMPORTANCE Low-dose aspirin use for chemoprevention of lung cancer risk remains controversial. OBJECTIVES To investigate the association between low-dose aspirin use and lung cancer risk, and to identify specific subgroups that may derive the most benefit from low-dose aspirin use. DESIGN, SETTING, AND PARTICIPANTS This nationwide, retrospective, cohort study used data from the Korean National Health Information Database from 2002 to 2015. Data analyses were performed from October 2016 to December 2018. Eligible participants (n = 12 969 400) were people aged 40 to 84 years who had undergone national health screening between 2009 and 2010 and had no history of lung cancer between 2006 and 2010 and no standard-dose aspirin use for 6 months between 2002 and 2010. MAIN OUTCOMES AND MEASURES The duration of low-dose aspirin use between January 2002 and December 2010 was calculated for each participant. Lung cancer was defined as the first recorded diagnosis of lung cancer-using International Statistical Classification of Diseases and Related Health Problems, Tenth Revision codes and expanding benefit coverage-between January 2011 and December 2015. RESULTS A total of 63 040 participants with a mean (SD) age of 66.4 (9.3) years received a diagnosis of lung cancer. Of these, 45 156 (71.6%) were men. The incidence rate of lung cancer was 98.8 per 100 000 person-years. The duration of low-dose aspirin use was none for 10 987 417 participants (84.7%), 1 to 2 years for 750 992 participants (5.8%), 3 to 4 years for 506 945 participants (3.9%), 5 to 6 years for 371 062 participants (2.9%), 7 to 8 years for 240 528 participants (1.9%), and 9 years for 112 456 participants (0.9%). Compared with no aspirin use, 5 to 6 years (adjusted hazard ratio, 0.96 [95% CI, 0.92-0.99]), 7 to 8 years (adjusted hazard ratio, 0.94 [95% CI, 0.90-0.99]), and 9 years (adjusted hazard ratio, 0.89 [95% CI, 0.84-0.94]) of aspirin use were significantly associated with reduced lung cancer risk. After stratified analysis, a significant reduction of lung cancer risk was observed among people aged 65 years or older and among people without diabetes. CONCLUSIONS AND RELEVANCE Although the use of low-dose aspirin for more than 5 years was associated with decreased risk of lung cancer, particularly among elderly participants and among people without diabetes, the observed effect size was quite modest. Future prospective studies are needed to determine whether there is a causal association.
DOI
10.1001/jamanetworkopen.2019.0185
Appears in Collections:
의과대학 > 의학과 > Journal papers
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE